Vše

Co hledáte?

Vše
Projekty
Výsledky výzkumu
Subjekty

Rychlé hledání

  • Projekty podpořené TA ČR
  • Významné projekty
  • Projekty s nejvyšší státní podporou
  • Aktuálně běžící projekty

Chytré vyhledávání

  • Takto najdu konkrétní +slovo
  • Takto z výsledků -slovo zcela vynechám
  • “Takto můžu najít celou frázi”

Substituted N-phenylitaconamides as inhibitors of mycobacteria and mycobacterial isocitrate lyase Context Sensitive Links 1 of 2 Substituted N-phenylitaconamides as inhibitors of mycobacteria and mycobacterial isocitrate lyase

Identifikátory výsledku

  • Kód výsledku v IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F71009396%3A_____%2F22%3AN0000010" target="_blank" >RIV/71009396:_____/22:N0000010 - isvavai.cz</a>

  • Výsledek na webu

    <a href="https://www.sciencedirect.com/science/article/pii/S0928098722001373?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/pii/S0928098722001373?via%3Dihub</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1016/j.ejps.2022.106252" target="_blank" >10.1016/j.ejps.2022.106252</a>

Alternativní jazyky

  • Jazyk výsledku

    angličtina

  • Název v původním jazyce

    Substituted N-phenylitaconamides as inhibitors of mycobacteria and mycobacterial isocitrate lyase Context Sensitive Links 1 of 2 Substituted N-phenylitaconamides as inhibitors of mycobacteria and mycobacterial isocitrate lyase

  • Popis výsledku v původním jazyce

    Novel antimycobacterial drugs are needed, especially those with dual activity against both actively growing and non-replicating subpopulations of mycobacteria. Isocitrate lyase (ICL) is one of proposed targets and this enzyme is inhibited by itaconic acid. That is why we have designed and prepared sixteen amides of itaconic acid and various anilines and amine antimicrobial drugs to evaluate them as potential inhibitors of ICL and antimycobacterial agents. N-Phenylitaconamides were prepared from itaconic anhydride and substituted anilines (yields 57-99%). They were characterized and evaluated against mycobacterial ICL and against actively growing mycobacteria (M. tuberculosis H37Rv, M. avium, two strains of M. kansasii). All derivatives showed antimycobacterial efficacy with minimum inhibitory concentrations starting from 125 mu M. M. kansasii was the most susceptible species. Itaconamides derived from sulfonamides or p-aminosalicylic acid were optimal for activity against extracellular mycobacteria. ICL1 was significantly inhibited by two compounds, with 2-methylene-4-[(4nitrophenyl)amino]-4-oxobutanoic acid 1k being the most potent (36% inhibition at 10 mu M), which was also more efficient than two comparators. Molecular docking revealed its mode of binding to the enzyme. Using in silico tools, physicochemical properties and structural features for drug-likeness and gastrointestinal absorption were evaluated.

  • Název v anglickém jazyce

    Substituted N-phenylitaconamides as inhibitors of mycobacteria and mycobacterial isocitrate lyase Context Sensitive Links 1 of 2 Substituted N-phenylitaconamides as inhibitors of mycobacteria and mycobacterial isocitrate lyase

  • Popis výsledku anglicky

    Novel antimycobacterial drugs are needed, especially those with dual activity against both actively growing and non-replicating subpopulations of mycobacteria. Isocitrate lyase (ICL) is one of proposed targets and this enzyme is inhibited by itaconic acid. That is why we have designed and prepared sixteen amides of itaconic acid and various anilines and amine antimicrobial drugs to evaluate them as potential inhibitors of ICL and antimycobacterial agents. N-Phenylitaconamides were prepared from itaconic anhydride and substituted anilines (yields 57-99%). They were characterized and evaluated against mycobacterial ICL and against actively growing mycobacteria (M. tuberculosis H37Rv, M. avium, two strains of M. kansasii). All derivatives showed antimycobacterial efficacy with minimum inhibitory concentrations starting from 125 mu M. M. kansasii was the most susceptible species. Itaconamides derived from sulfonamides or p-aminosalicylic acid were optimal for activity against extracellular mycobacteria. ICL1 was significantly inhibited by two compounds, with 2-methylene-4-[(4nitrophenyl)amino]-4-oxobutanoic acid 1k being the most potent (36% inhibition at 10 mu M), which was also more efficient than two comparators. Molecular docking revealed its mode of binding to the enzyme. Using in silico tools, physicochemical properties and structural features for drug-likeness and gastrointestinal absorption were evaluated.

Klasifikace

  • Druh

    J<sub>imp</sub> - Článek v periodiku v databázi Web of Science

  • CEP obor

  • OECD FORD obor

    30104 - Pharmacology and pharmacy

Návaznosti výsledku

  • Projekt

    <a href="/cs/project/GJ20-19638Y" target="_blank" >GJ20-19638Y: Design a studium nových antimikrobních látek účinných na rezistentní a biofilm-produkující gram-pozitivní bakterie</a><br>

  • Návaznosti

    P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Ostatní

  • Rok uplatnění

    2022

  • Kód důvěrnosti údajů

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Údaje specifické pro druh výsledku

  • Název periodika

    European Journal of Pharmaceutical Sciences

  • ISSN

    0928-0987

  • e-ISSN

    1879-0720

  • Svazek periodika

    176

  • Číslo periodika v rámci svazku

    106252

  • Stát vydavatele periodika

    NL - Nizozemsko

  • Počet stran výsledku

    8

  • Strana od-do

    1-8

  • Kód UT WoS článku

    000839196000010

  • EID výsledku v databázi Scopus

    2-s2.0-85134358236